Compare Essex Property Trust, Inc. (ESS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Essex Property Trust, Inc. trades at $282.1 (market cap $18.15B), while State Street SPDR S&P Biotech ETF trades at $158.81. The key difference: Essex Property Trust, Inc. pays a 3.93% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Essex Property Trust, Inc. nearer its low. Which is the better fit depends on your goals.
| ESS | XBI | |
|---|---|---|
Market Cap | $18.15B | — |
Sector | Real Estate | Broad Market / Factor |
52-Week High | $298.33 | $164.28 |
52-Week Low | $239.61 | $86.92 |
Enterprise Value | $24.75B | — |
Dividend Yield | 3.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $281.92, down 0.46% on the day, with a bearish technical signal from moving averages and oscillators. The company reported a Q2 2026 EPS miss ($0.97 vs. $1.46 expected) but raised full-year guidance, reflecting strong property NOI growth. Revenue reached $1.89B in 2025 with a net income margin of 35.48%, though profitability is projected to moderate in 2026. Recent news highlights institutional buying by Amundi and recognition as a top GreenTech company.
The outlook is mixed: raised guidance and solid fundamentals support upside toward the $305.86 consensus price target, but technical weakness and a high debt load pose near-term risks. Investor sentiment is cautiously optimistic, with 40% of analysts rating the stock a Buy, though the bearish technical picture suggests potential volatility ahead.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
